Ginsenoside Rg1 (PPT Ginseng Saponin · Cognitive Stimulation · Haematopoiesis · Anti-fatigue)

Compound	Ginsenoside Rg1 (Panaxoside Rg1)
Chemical class	Terpenoid — Triterpene Saponin (Dammarane-type protopanaxatriol glycoside; PPT-type)
CAS	22427-39-0
Primary source	Panax ginseng (Asian ginseng root), Panax notoginseng (tienchi/sanqi ginseng)
Key applications	Cognitive stimulation; anti-fatigue; immune modulation; haematopoiesis support; notoginsenoside-R1 related
Claim strength	Moderate
Typical form	Ginseng extract standardised to total ginsenosides (co-delivered with Rb1); Rg1 isolate (≥98%)
Buy from Herbuno	Asian Ginseng Extract Powder → Korean Ginseng Liquid Extract (Water Soluble) - Panax ginseng →

Name origin: Same etymology as Rb1 (Panax = panacea; -oside = glycoside). “Rg1” denotes its chromatographic position and structural class — PPT (protopanaxatriol)-type ginsenoside. Rg1 differs from Rb1 at the core scaffold level: Rb1 is based on 20(S)-protopanaxadiol (two hydroxyl groups on the tetracyclic triterpene), while Rg1 is based on 20(S)-protopanaxatriol (three hydroxyl groups, with one at position 6). This structural difference places Rg1’s sugar chains at C-6 and C-20 (versus Rb1’s C-3 and C-20), producing significantly different pharmacological properties — particularly CNS excitatory versus inhibitory character. Key pharmacological distinctions from Rb1: Where Rb1 is primarily neuroprotective and calming, Rg1 is primarily cognitive-stimulating, haematopoiesis-promoting, and immunostimulatory. Rg1’s CNS effects include: enhanced acetylcholine release, stimulation of neurotrophic factor production (NGF, BDNF), and NMDA receptor modulation (low-dose facilitation). These effects are consistent with traditional ginseng use for mental clarity and performance, making Rg1 the “nootropic” ginsenoside of the pair. Panax notoginseng context: Rg1 is also a primary ginsenoside in Panax notoginseng (sanqi/tienchi), used extensively in TCM for haemostasis, trauma healing, and cardiovascular support. P. notoginseng extracts are the most widely prescribed botanical cardiovascular product in China (Yunnan Baiyao and related formulations).

---

Evidence for Ginsenoside Rg1 Applications

Cognitive stimulation and nootropic: Rg1 enhances ACh release in hippocampal slices and promotes NGF (nerve growth factor) and BDNF expression in cortical and hippocampal neurons. Multiple animal studies show improved learning, memory consolidation, and spatial navigation with Rg1 administration. Human clinical data from whole ginseng extracts — primarily using validated cognitive tests (MMSE, ADAS-cog) — support cognitive enhancement in healthy adults and early cognitive impairment. The cognitive-stimulating Rg1 effects complement Rb1’s neuroprotective Rb1 effects in whole extract formulations. Claim strength: Moderate.

Haematopoiesis and immune support: Rg1 promotes proliferation of haematopoietic stem cells (HSCs) and progenitor cells in bone marrow — stimulating red and white blood cell production. This is the pharmacological basis for ginseng’s traditional use in post-illness recovery, anaemia, and immune deficiency contexts. Rg1 also activates NK cells and macrophages via TLR4 signalling. Claim strength: Moderate (animal; traditional clinical).

Anti-fatigue and physical performance: Multiple human RCTs with ginseng extract demonstrate reduced perceived fatigue, improved exercise performance markers (VO2max, time to exhaustion), and reduced oxidative stress post-exercise. Rg1 and Re are considered primary contributors to these effects via mitochondrial biogenesis stimulation and glycogen-sparing effects. Claim strength: Moderate (human RCTs for whole extract; Rg1-specific attribution moderate).

---

Frequently Asked Questions — Ginsenoside Rg1

Is Rg1 a stimulant?
Rg1 has stimulant-like CNS effects — increased alertness, enhanced cognitive processing, improved physical endurance — but through mechanisms fundamentally different from classical stimulants (caffeine, amphetamines). Rg1 enhances cholinergic and dopaminergic neurotransmission without receptor overstimulation or sympathomimetic cardiovascular effects. It does not produce withdrawal on cessation (unlike caffeine or nicotine), does not cause tolerance in most animal models, and has no addiction potential. In sports anti-doping context, ginsenosides including Rg1 are not on the WADA prohibited list.

What is notoginsenoside R1 and how does it relate to Rg1?
Notoginsenoside R1 is a unique ginsenoside found specifically in Panax notoginseng — it is not present in P. ginseng or P. quinquefolius. Structurally, notoginsenoside R1 is a PPT-type ginsenoside (same class as Rg1) but with a different sugar chain arrangement (xylose instead of glucose at one position). Pharmacologically, notoginsenoside R1 has potent cardiovascular protective effects (anti-platelet, anti-ischaemic, vasodilatory) making it the primary distinctive bioactive of P. notoginseng versus other ginseng species. It co-occurs with Rg1 in tienchi/sanqi preparations.

Does red ginseng have more Rg1 than white ginseng?
Processing changes ginsenoside profiles significantly. Red ginseng (steamed at 120°C for several hours) converts some Rb1 to Rg3 and other rare ginsenosides via deglycosylation and epimerisation. The Rg1 content in red vs white ginseng is actually relatively similar — Rg1 is more thermostable than Rb1 and does not convert as readily during steaming. What red ginseng processing primarily adds is Rg3, Rh2, and compound K — ginsenosides with documented anticancer and immunomodulatory activity that are essentially absent from white (unprocessed) ginseng.

How is Rg1 different from Rg3?
Rg1 is a PPT-type ginsenoside with excitatory cognitive/haematopoietic effects. Rg3 is a PPD-type ginsenoside produced only in red ginseng processing (from Rb1 via steaming). Rg3 has primarily anticancer and anti-metastatic effects (inhibits angiogenesis, reduces MMP expression) with no significant cognitive-stimulating properties. Both have their own research programmes — Rg3 appears in some Korean pharmaceutical formulations for cancer supportive care. They share only the “Rg” chromatographic designation prefix; their pharmacology is not related.

Related compounds: Ginsenoside Rb1, Astragaloside IV, Boswellic Acid, Andrographolide

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery